Emmaus Life Sciences, Inc. (EMMA)
Market Cap | 14.37M |
Revenue (ttm) | 21.91M |
Net Income (ttm) | -12.61M |
Shares Out | 49.56M |
EPS (ttm) | -0.47 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 500 |
Open | 0.320 |
Previous Close | 0.246 |
Day's Range | 0.320 - 0.320 |
52-Week Range | 0.071 - 0.600 |
Beta | 1.92 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 12, 2019 |
About EMMA
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an a... [Read more]
Financial Performance
In 2022, EMMA's revenue was $18.39 million, a decrease of -10.77% compared to the previous year's $20.61 million. Losses were -$10.69 million, -32.99% less than in 2021.
Financial StatementsNews

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
TORRANCE, Calif. , May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certif...

Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
TORRANCE, Calif. , May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...

Emmaus Life Sciences Provides Interim Shipment Data
TORRANCE, Calif. , April 3, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended March 31...

Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , March 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today repor...

Dr. Niihara Meets with Local Indian Governor
Cites Large, Unserved Needs of Sickle Cell Disease Patients TORRANCE, Calif. , Dec. 20, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairm...

Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®
Celebrity Event Hosted in Mumbai, India TORRANCE, Calif., Dec. 19, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), announced today that Dr. Yutaka Niihara, Chairman and Chief Executiv...

Endari® Receives Kuwaiti Marketing Authorization
Kuwait is Third Gulf Cooperation Council Country to Approve Endari ® TORRANCE Calif. , Dec. 7, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment,...

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health
Company Receives First Major Purchase Order in Saudi Arabia TORRANCE, Calif. , Nov. 17, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announ...

Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , Nov. 14, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...

Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®
Nationally Syndicated Radio Programming Will Educate and Support SCD Patients TORRANCE, Calif. , Sept. 28, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceu...

Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today report...

Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor
Acorn Management Partners Will Develop and Implement a Market Awareness Program Targeting Financial Professionals TORRANCE, Calif. , July 12, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: E...

Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
TORRANCE, Calif. , May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...

Emmaus Life Sciences to Present at Investor Conferences in May
TORRANCE, Calif. , April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today ann...

Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology
Sickle Cell Patients Treated With Endari ® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline Adverse Events Among These Pati...

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
TORRANCE, Calif. , March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today repor...

Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List
Florida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients TORRANCE, Calif. , March 29, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in...

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®
TORRANCE, Calif. , March 23, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announ...

Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology
TORRANCE, Calif., March 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announc...

Insiders Buying These 3 Penny Stocks
Asian stock markets slumped on Tuesday amid escalating crisis in Russia and Ukraine. Investors, meanwhile, focused on some notable insider trades.

Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference
TORRANCE, Calif., Jan. 4, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announce...

Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting
TORRANCE, Calif., Dec. 14, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announc...

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th
TORRANCE, Calif., Dec. 9, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announce...

Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition
TORRANCE Calif., Dec. 6, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced...

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights
TORRANCE, Calif., Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reporte...